Bifunctional compounds

Patent metadata

Field	Value
Publication number	US-11236103-B2
Application number	US-201916522481-A
Country	US
Kind code	B2
Filing date	Jul 25, 2019
Priority date	Jul 27, 2018
Publication date	Feb 1, 2022
Grant date	Feb 1, 2022

Abstract

The present application provides compounds that modulate CDK protein function. Methods of making the compounds, compositions containing the compounds, and uses of the compounds for treating or ameliorating of diseases, disorders, or conditions associated with CDK proteins, are also disclosed.

First claim

What is claimed is:

1. A compound of Formula (II):

or a pharmaceutically acceptable salt thereof, wherein:
R 1 is

wherein R 1 is optionally substituted with one or more R A ;
each n is independently an integer of 1, 2 or 3;
each R 2a and R 2b is independently H, deuterium, halogen, or C 1 -C 6 alkyl;
each R 3 is independently H, deuterium, C 1 -C 6 alkyl,

each R A is independently deuterium, hydroxyl, halogen, cyano, nitro, optionally substituted C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkyl, C 1 -C 6 haloalkoxy, optionally substituted amino, C 1 -C 6 alkylamino, amino(C 1 -C 6 alkyl), —(C═O)NR 10a R 10b , (C 1 -C 6 alkoxy)C 1 -C 6 alkyl, —O—(C 1 -C 6 alkoxy)C 1 -C 6 alkyl, or optionally substituted C 3 -C 7 cycloalkyl;
each of R 4 and R 6 is independently H, halogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy, optionally substituted C 3 -C 7 cycloalkyl(C 1 -C 3 alkyl), or optionally substituted C 3 -C 7 cycloalkyl;
each of R 5a , R 5b , and R 5c is independently H or C 1 -C 6 alkyl;
each of R 7a and R 7b is independently H, optionally substituted C 1 -C 6 alkyl, optionally substituted C 2 -C 6 alkenyl, optionally substituted C 2 -C 6 alkynyl, optionally substituted C 6 -C 10 aryl, optionally substituted 5 to 10 membered heteroaryl, optionally substituted C 7 -C 14 aralkyl, optionally substituted 3 to 10 membered heterocyclyl, or optionally substituted C 3 -C 8 carbocyclyl;
each of R 8a and R 8b is independently H, halogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkyl, C 1 -C 6 haloalkoxy, or C 3 -C 8 carbocyclyl;
each of R 9a and R 9b is independently H, optionally substituted C 1 -C 6 alkyl, optionally substituted C 6 -C 10 aryl, optionally substituted C 7 -C 14 aralkyl, or optionally substituted C 3 -C 8 carbocyclyl;
each R 10a and R 10b is independently H or C 1 -C 6 alkyl; or R 10a and R 10b together with the nitrogen atom to which they are attached form an optionally substituted 5 or 6 membered heterocyclyl optionally substituted with one or more R 11 ;
each R 11 is independently C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkyl, C 1 -C 6 haloalkoxy, (C 1 -C 6 alkoxy)C 1 -C 6 alkyl, —O—(C 1 -C 6 alkoxy)C 1 -C 6 alkyl, optionally substituted amino, halogen, or cyano; or two geminal R 11 form oxo;
Q is CH 2 or C═O;
L 1 is a bond,

wherein the asterisk * indicates the point of connection to X 1 ;
each of Z 1a , Z 1b Z 1c , Z 1d , Z 1e , and Z 1f is independently a bond or —(CR a R b ) q1 —;
Z 2 is —(CR c R d ) q2 —;
Z 3 is a bond, O or NR 12g ;
each of R a , R b , R c and R d is independently H, halogen, hydroxyl, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy, or optionally substituted C 3 -C 6 cycloalkyl;
each q1 and q2 is independently an integer of 1, 2, or 3;
each X a and X b is independently O or S;
each Ring A is independently phenyl or a five to six membered heteroaryl, each optionally substituted with one or more R 11 ;
each of Y 1 , Y 2 , Y 3 , Y 4 , Y 5 and Y 6 is —NR 12h —, —O—, or —S—;
each R 12a , R 12b , R 12c , R 12d , R 12e , R 12f , R 12g and R 12h is independently H or C 1 -C 6 alkyl;
each of m1, m2, m3, m4, m5, m6, k1, k2, k3, k4, k5, k6, p1, p2, p3, p4, p5, and p6 is independently an integer of 0, 1, 2, or 3;
L 2 is a bond, —(CH 2 ) 1-6 NH—, —(CH 2 ) 0-6 —C(═O)—, or —(CH 2 ) 0-3 —C(═O)NR 13 —;
R 13 is H or C 1 -C 6 alkyl;
X 1 is C 1 -C 15 alkylene or heteroalkylene; and
Ring B is phenyl or a 6 membered heteroaryl, optionally substituted with one or more R 11 .

2. The compound of claim 1 , wherein the compound has the structure of Formula (II′):

or a pharmaceutically acceptable salt thereof.

3. The compound of claim 1 , wherein R 1 is

4. The compound of claim 1 , wherein R 2a is H or R 2b is C 1 -C 6 alkyl.

5. The compound of claim 1 , wherein R 3 is H.

6. The compound of claim 1 , wherein n is an integer of 2.

7. The compound of claim 1 , wherein R 1 is substituted with one R A and wherein R A is halogen or optionally substituted C 1 -C 6 alkyl.

8. The compound of claim 1 , wherein each of R 5b and R 5c is H.

9. The compound of claim 1 , wherein L 1 is

10. The compound of claim 9 , wherein each of R 12 and R 12b is H; X a is O; Zia is a bond or —(CH 2 ) 1-3 —; and m1 is an integer of 0 or 1.

11. The compound of claim 1 , wherein L 1 is

12. The compound of claim 11 , wherein each of R 12c and R 12d is H; X a is O; Z 2 is —CH 2 —; —Z 1b is a bond or —(CH 2 ) 1-3 —; and m2 is an integer of 0 or 1.

13. The compound of claim 1 , wherein L 1 is *—Z 1e Z 3 —(CH 2 ) m5 — and Z 3 is —NR 12g —.

14. The compound of claim 1 , wherein R 12g is H; Z 1e is a bond or —(CH 2 ) 1-3 —; and m5 is an integer of 0 or 1.

15. The compound of claim 1 , wherein L 1 is

16. The compound of claim 15 , wherein R 12f is H; Z 1d is a bond or —(CH 2 ) 1-3 —; X a is O; Ring A is phenyl; Y 4 is —O— or —NH—; and each of k4, p4, and m4 is independently an integer of 0 or 1.

17. The compound of claim 1 , wherein L 1 is

and Z 3 is —NR 12g —.

18. The compound of claim 17 , wherein R 12g is H; Z 1e is a bond or —(CH 2 ) 1-3 —; Ring A is phenyl; Y 5 is —O— or —NH—; and each of k5, p5, and m5 is independently an integer of 0 or 1.

19. The compound of claim 1 , wherein L 1 is

20. The compound of claim 19 , wherein each of R 12c and R 12d is H; X a is O; Z 1b is a bond or —(CH 2 ) 1-3 —; Z 2 is —(CH 2 ) 1-3 —; Ring A is phenyl; and each of k2, p2, and m2 is independently an integer of 0 or 1.

21. The compound of claim 1 , wherein L 1 is

22. The compound of claim 21 , wherein Z 1f is a bond or —(CH 2 ) 1-3 —; and m6 is an integer of 0 or 1.

23. The compound of claim 1 , wherein X 1 is C 1 -C 8 alkylene.

24. The compound of claim 1 , wherein X 1 is —[(CH 2 ) 2 O] 1-5 —, —[(CH 2 ) 2 O] 1-5 (CH 2 ) 2 —, or —(CH 2 ) 1-3 —NR 14 —(CH 2 ) 1-3 —; and wherein R 14

Assignees

• Biotheryx Inc

Inventors

• Chan Kyle W H
• Chourasia Aparajita Hoskote
• Erdman Paul E
• Fung Leah
• Hecht David Aaron
• Mercurio Frank
• Sullivan Robert
• Vacca Joseph P

Classifications

• C07D495/04 Primary

  Ortho-condensed systems · CPC title

• A61K31/506

  not condensed and containing further heterocyclic rings · CPC title

• C07D401/14

  containing three or more hetero rings · CPC title

• A61K31/4545

  containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine · CPC title

• C07D417/14

  containing three or more hetero rings · CPC title